Comparison of Syndecan-1 Immunohistochemical Expression in Lobular and Ductal Breast Carcinoma with Nodal Metastases

被引:6
作者
Mise, Ivana [1 ]
Vucic, Majda [2 ]
机构
[1] Univ Hosp Sestre Milosrdnice, Dept Clin Cytol, Zagreb, Croatia
[2] Univ Hosp Sestre Milosrdnice, Dept Pathol, Zagreb, Croatia
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; SQUAMOUS-CELL CARCINOMA; C-TERMINAL FRAGMENT; HEPARAN-SULFATE; PROGNOSTIC VALUE; E-CADHERIN; CANCER PATIENTS; PROGRESSION; SURFACE; CD138;
D O I
10.1155/2018/9432375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Syndecan-1 (Sdc1) is a transmembrane heparan sulfate proteoglycan, an extracellular matrix receptor involved in intercellular communication, proliferation, angiogenesis, and metastasis. This study determined and compared Sdc1 expression in the tumor cells and stroma of 30 invasive lobular and 30 invasive ductal breast carcinomas (ILCs/IDCs), also in the axillary node metastases of ductal type, and correlated it with clinical and tumor parameters. Sdc1 was expressed in the epithelium of 90% carcinoma of both histological types. Also, it was most frequently expressed in their tumor stroma, but in ILC, stromal expression was negative in 40%. Sdc1 was expressed in 86.7% of the metastatic epithelium of IDC nodal metastases (in even 50% as high expression), while the nodal stroma was negative in 46.7%. Primary IDC showed a negative correlation between epithelial Sdc1 and progesterone receptors (PRs), whereas ILC showed a positive correlation between stromal Sdc1 and histological gradus. In the metastatic epithelium, Sdc1 was negatively correlated with a patient's age, estrogen receptors (ERs), and PRs in the primary tumors, while the stroma of metastases demonstrated a positive correlation with the focus number in primary tumors and a negative correlation with PRs in primary tumors. This research revealed identical overall epithelial Sdc1 expression in both breast carcinomas with no statistically significant difference in its stromal expression and confirmed the role of Sdc1 in the progression of both tumor types and in the development of ductal carcinoma's metastatic potential.
引用
收藏
页数:12
相关论文
共 81 条
[1]   Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine [J].
Akl, Mohamed R. ;
Nagpal, Poonam ;
Ayoub, Nehad M. ;
Prabhu, Sathyen A. ;
Gliksman, Matthew ;
Tai, Betty ;
Hatipoglu, Ahmet ;
Goy, Andre ;
Suh, K. Stephen .
ONCOTARGET, 2015, 6 (30) :28693-28715
[2]   Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis [J].
Andersen, Niels F. ;
Kristensen, Ida B. ;
Preiss, Birgitte S. ;
Christensen, Jacob H. ;
Abildgaard, Niels .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (03) :211-217
[3]   Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations [J].
Anttonen, A ;
Leppä, S ;
Heikkilä, P ;
Grenman, R ;
Joensuu, H .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (07) :451-457
[4]   Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy [J].
Anttonen, A ;
Leppä, S ;
Ruotsalainen, T ;
Alfthan, H ;
Mattson, K ;
Joensuu, H .
LUNG CANCER, 2003, 41 (02) :171-177
[5]   High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery [J].
Anttonen, A ;
Heikkilä, P ;
Kajanti, M ;
Jalkanen, M ;
Joensuu, H .
LUNG CANCER, 2001, 32 (03) :297-305
[6]   Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype [J].
Baba, Fusun ;
Swartz, Kathryn ;
van Buren, Regina ;
Eickhoff, Jens ;
Zhang, Yong ;
Wolberg, William ;
Friedl, Andreas .
BREAST CANCER RESEARCH AND TREATMENT, 2006, 98 (01) :91-98
[7]   Invasive lobular carcinoma: to grade or not to grade [J].
Bane, AL ;
Tjan, S ;
Parkes, RK ;
Andrulis, I ;
O'Malley, FP .
MODERN PATHOLOGY, 2005, 18 (05) :621-628
[8]   High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis [J].
Barbareschi, M ;
Maisonneuve, P ;
Aldovini, D ;
Cangi, MG ;
Pecciarini, L ;
Mauri, FA ;
Veronese, S ;
Caffo, O ;
Lucenti, A ;
Palma, PD ;
Galligioni, E ;
Doglioni, C .
CANCER, 2003, 98 (03) :474-483
[9]   Syndecan-1 regulates αvβ3 and αvβ5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor [J].
Beauvais, DeannaLee M. ;
Ell, Brian J. ;
McWhorter, Andrea R. ;
Rapraeger, Alan C. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (03) :691-705
[10]   Syndecans in tumor cell adhesion and signaling [J].
Beauvais D.M. ;
Rapraeger A.C. .
Reproductive Biology and Endocrinology, 2 (1)